FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912104619> ?p ?o ?g. }

• W2912104619 endingPage "2266" @default.
• W2912104619 startingPage "2266" @default.
• W2912104619 abstract "Abstract Introduction: Indolent non-Hodgkin lymphomas (iNHL), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), are slow-growing lymphoid malignancies with high response rates to first-line treatment, but most patients (pts) will eventually relapse after initial response to treatment. For those with refractory disease (relapse ≤ 6 months after ending treatment), outcomes are worse. A number of treatment options based on chemo- and/or immunotherapy exist for pts with relapsed/refractory (R/R) iNHL, but currently there is no single standard treatment approach. There is a need to better understand the reported efficacy of available systemic treatments for R/R FL and MZL to guide treatment of iNHL. Methods: A SLR was carried out in accordance with PRISMA guidelines on September 1, 2017. Publications from MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov databases, as well as proceedings from the European Hematology Association and American Society of Clinical Oncology conferences held from 2015 to 2017, the International Conference on Malignant Lymphomas from 2013, 2015, and 2017, and from the American Society of Hematology, and European Society for Medical Oncology conferences from 2014 to 2016, were included. Studies were limited to articles published in English, sample sizes ≥ 40, and studies evaluating systemic therapy for adults with any-stage R/R FL, MZL, or mixed histologies with ≥ 70% R/R FL/MZL pts. Controlled or uncontrolled clinical trials and observational studies were included. Studies varied with respect to prior treatment received and pt response to prior treatment at enrollment. Pts were classified as relapsed, refractory, refractory to rituximab (R-refractory including double-refractory pts), R/R but sensitive or naïve to rituximab, or as general R/R if the type of relapse and/or refractoriness was not specified. Efficacy measures included overall response rate, complete response rate, progression-free survival (PFS), and duration of response (DoR). Relevant interventions included bendamustine (B) (alone or with rituximab [BR] or obinutuzumab [O+B]), idelalisib (ID), ibrutinib (IB), copanlisib (C), lenalidomide (L) (alone or with rituximab [R2]), R + cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP), R + cyclophosphamide + vincristine + prednisone (R-CVP), and R + chlorambucil (R-Chl). Results: Of 58 publications identified representing 36 studies involving 3,759 pts: 1 study reported on R2, 2 on L, 5 on B, 6 on BR, 3 on ID, 3 on IB, 2 on C, 1 on O+B, 1 on R-CHOP, and 12 on R alone. After excluding studies that did not meet criteria for similarity, 19 studies reporting outcomes in iNHL pts were included. Six studies each reported on general R/R pts or R-refractory pts, 4 studies reported on pts with relapsed disease, and 2 studies each reported on pts with refractory disease or R-naïve/sensitive refractory disease. PFS in the general R/R population (n = 1,668) ranged from 4.4 months (mo) in pts treated with L to 17.9 mo in pts treated with BR. Only 1 study reported DoR for pts in the general R/R population. In relapsed pts, PFS was only reported or reached in 1 study (22.9 mo) and DoR ranged from 21.0 to 41.9 mo for BR. In R-refractory pts, PFS ranged from 9.3 mo in B-treated pts to 29.2 mo in O+B-treated pts. DoR ranged from 9.2 to 22.6 mo. BR was investigated in the widest variety of disease subsets (4) with PFS ranging from 17.9 mo in the general R/R population to 34.2 mo in the R-naïve/sensitive R/R population (Table). Outcomes are likely to have been influenced by pt and disease characteristics (e.g., relapsed vs refractory, rituximab sensitive vs refractory, FL International Prognostic Index risk) and response criteria used (Cheson 1999, Cheson 2007, Laboratory of Experimental Oncology and Radiobiology [LEXOR], or unknown). Conclusions: In pts with R/R iNHL (FL and MZL), there is significant variation in reported response and survival outcomes following systemic therapy. Currently, there is no clear standard of care for R/R iNHL, as demonstrated by the use of 9 different therapies across 19 studies identified in this SLR. Limited information is available on treatment outcomes for pts with different disease status and further studies are needed to determine the most appropriate treatment approach for specific subgroups of pts with R/R iNHL. Disclosures Bachy: Roche: Honoraria; Beigene: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Takeda: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees. Fox:Celgene: Consultancy, Other: travel support, Speakers Bureau; Roche: Consultancy, Other: travel support, Research Funding, Speakers Bureau; Gilead: Consultancy, Other: travel support, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: travel support, Speakers Bureau; Abbvie: Consultancy, Other: travel support, Research Funding, Speakers Bureau; Sunesis: Consultancy. Howlett:Celgene: Employment, Equity Ownership. Snedecor:Celgene: Research Funding. Franek:Celgene Corp.: Consultancy. Zaidi:Celgene Corp.: Consultancy. Tabah:Celgene Corporation: Employment." @default.
• W2912104619 created "2019-02-21" @default.
• W2912104619 creator A5015057739 @default.
• W2912104619 creator A5019034145 @default.
• W2912104619 creator A5053019069 @default.
• W2912104619 creator A5058812106 @default.
• W2912104619 creator A5066598802 @default.
• W2912104619 creator A5066846305 @default.
• W2912104619 creator A5070363076 @default.
• W2912104619 creator A5072175178 @default.
• W2912104619 creator A5082526059 @default.
• W2912104619 date "2018-11-29" @default.
• W2912104619 modified "2023-09-26" @default.
• W2912104619 title "Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)" @default.
• W2912104619 doi "https://doi.org/10.1182/blood-2018-99-112892" @default.
• W2912104619 hasPublicationYear "2018" @default.
• W2912104619 type Work @default.
• W2912104619 sameAs 2912104619 @default.
• W2912104619 citedByCount "0" @default.
• W2912104619 crossrefType "journal-article" @default.
• W2912104619 hasAuthorship W2912104619A5015057739 @default.
• W2912104619 hasAuthorship W2912104619A5019034145 @default.
• W2912104619 hasAuthorship W2912104619A5053019069 @default.
• W2912104619 hasAuthorship W2912104619A5058812106 @default.
• W2912104619 hasAuthorship W2912104619A5066598802 @default.
• W2912104619 hasAuthorship W2912104619A5066846305 @default.
• W2912104619 hasAuthorship W2912104619A5070363076 @default.
• W2912104619 hasAuthorship W2912104619A5072175178 @default.
• W2912104619 hasAuthorship W2912104619A5082526059 @default.
• W2912104619 hasConcept C121332964 @default.
• W2912104619 hasConcept C126322002 @default.
• W2912104619 hasConcept C142424586 @default.
• W2912104619 hasConcept C143998085 @default.
• W2912104619 hasConcept C194409129 @default.
• W2912104619 hasConcept C2777058707 @default.
• W2912104619 hasConcept C2779338263 @default.
• W2912104619 hasConcept C535046627 @default.
• W2912104619 hasConcept C71924100 @default.
• W2912104619 hasConcept C87355193 @default.
• W2912104619 hasConceptScore W2912104619C121332964 @default.
• W2912104619 hasConceptScore W2912104619C126322002 @default.
• W2912104619 hasConceptScore W2912104619C142424586 @default.
• W2912104619 hasConceptScore W2912104619C143998085 @default.
• W2912104619 hasConceptScore W2912104619C194409129 @default.
• W2912104619 hasConceptScore W2912104619C2777058707 @default.
• W2912104619 hasConceptScore W2912104619C2779338263 @default.
• W2912104619 hasConceptScore W2912104619C535046627 @default.
• W2912104619 hasConceptScore W2912104619C71924100 @default.
• W2912104619 hasConceptScore W2912104619C87355193 @default.
• W2912104619 hasIssue "Supplement 1" @default.
• W2912104619 hasLocation W29121046191 @default.
• W2912104619 hasOpenAccess W2912104619 @default.
• W2912104619 hasPrimaryLocation W29121046191 @default.
• W2912104619 hasRelatedWork W2006258736 @default.
• W2912104619 hasRelatedWork W2037787023 @default.
• W2912104619 hasRelatedWork W2060147037 @default.
• W2912104619 hasRelatedWork W2061197963 @default.
• W2912104619 hasRelatedWork W2104022636 @default.
• W2912104619 hasRelatedWork W2119639290 @default.
• W2912104619 hasRelatedWork W2766712561 @default.
• W2912104619 hasRelatedWork W2888723857 @default.
• W2912104619 hasRelatedWork W2948510621 @default.
• W2912104619 hasRelatedWork W3032864963 @default.
• W2912104619 hasVolume "132" @default.
• W2912104619 isParatext "false" @default.
• W2912104619 isRetracted "false" @default.
• W2912104619 magId "2912104619" @default.
• W2912104619 workType "article" @default.